STAT Plus: 9 big takeaways from the $74 billion Bristol-Celgene deal
ALEX HOGAN/STAT
The proposed merger of Bristol-Myers Squibb and Celgene have sweeping implications for the drug industry. Here are some of the major ones.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario